The rise and fall of long-lived humoral immunity: Terminal differentiation of plasma cells in health and disease

Immunological Reviews

Volumn 194, Issue , 2003, Pages 61-76

  O'Connor, Brian P ^a   Gleeson, Michael W ^a   Noelle, Randolph J ^a   Erickson, Loren D ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW; CANCER CELL; CELL DIFFERENTIATION; CELL FATE; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELLULAR IMMUNITY; GERMINAL CENTER; HELPER CELL; HOMEOSTASIS; HUMORAL IMMUNITY; IMMUNE RESPONSE; LONGEVITY; MEMORY CELL; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; REVIEW; STEM CELL; T LYMPHOCYTE;

ANIMALS; ANTIBODY FORMATION; CELL DIFFERENTIATION; DISEASE; HEALTH; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 0038675195     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00055.x     Document Type: Review

References (124)

1. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001;2:1103-1108.
2. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000;176:154-170.
3. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165:S49-S52.
4. Erickson LD, et al. B cell immunopoiesis: visualizing the impact of CD40 engagement on the course of T cell-independent immune responses in an Ig transgenic system. Eur J Immunol 2000;30:3121-3131.
5. Sze DM, Toellner KM, Garcia de Vinuesa C, Taylor DR, MacLennan IC. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J Exp Med 2000;192:813-821.
6. Foy T, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol 1996;14:591-617.
7. MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12:117-139.
8. Kelsoe G. In situ studies of the germinal center reaction. Adv Immunol 1995;60:267-288.
9. Banchereau J, et al. The CD40 antigen and its ligand. [Review] Annu Rev Immunol 1994;12:881-922.
10. Noelle RJ. CD40 and its ligand in host defense. Immunity 1996;4:415-419.
11. Gray D, et al. B-T lymphocyte interactions in the generation and survival of memory cells. Immunol Rev 1996;150:45-61.
12. Garcia de Vinuesa C, MacLennan 1C, Holman M, Klaus GG. Anti-CD40 antibody enhances responses to polysaccharide without mimicking T cell help. Eur J Immunol 1999;.29:3216-3224.
13. Kuhne MR, et al. Assembly and regulation of the CD40 receptor complex in human B cells. J Exp Med 1997;186:337-342.
14. Pullen SS, Miller HG, Everdeen DS, Dang TTA, Crute JJ, Kehry MR. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998;37:11836-11845.
15. Pullen SS, Dang TT, Crute JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 1999;.274:14246-14254.
16. Ahonen CL, et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol 2002;3:451-456.
17. Yasui T, et al. Dissection of b cell differentiation during primary immune responses in mice with altered CD40 signals. Int Immunol 2002;14:319-329.
18. Erickson LD, et al. Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. J Clin Invest 2002;109:613-620.
19. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-bred plasma cells. Immunity 1998;8:363-372.
20. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A. Survival of long-lived plasma cells is independent of antigen. Int Immunol 1998;10:1703-1711.
21. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002;14:517-521.
22. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-2202.
23. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol 2000;165:5462-5471.
24. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994;77:297-306.
25. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
26. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. BL1MP-I mediates extinction of major histocompatibility class 11 transactivator expression in plasma cells. Nat Immunol 2000;1:526-532.
27. Reimold AM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-307.
28. Falini B, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/1RF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084-2092.
29. Benner R, Hijmans W, Haaijman JJ. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol 1981;46:1-8.
30. Koch G, Osmond DG, Julius MH, Benner R. The mechanism of thymus-dependent antibody formation in bone marrow. J Immunol 1981;126:1447-1451.
31. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 2000;407:636-642.
32. Arpin C, Banchereau J, Liu YJ. Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing. J Exp Med 1997;186:931-940.
33. Tangye SG, Avery DT, Hodgkin PD. A division-linked mechanism for the rapid generation of 1g-secreting cells from human memory B cells. J Immunol 2003;170:261-269.
34. Barrington RA, Pozdnyakova O, Zafari MR, Benjamin CD, Carroll MC. B lymphocyte memory: role of stromal cell complement and FcgammaR11B receptors. J Exp Med 2002;196:1189-1199.
35. -/- mice is rescued by adjuvants without improvement in germinal center development. J Immunol 2000;165:3119-3127.
36. Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993;178:1023-1031.
37. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-3582.
38. Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34(+) hematopoietic progenitors. Clin Cancer Res 2002;8:3198-3204.
39. O'Connor BP, Cascalho M, Noelle RJ. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med 2002;195:737-745.
40. Freitas AA, Rocha B. Population biology of lymphocytes: the flight for survival. Annu Rev Immunol 2000;18:83-111.
41. Antia R, Pilyugin SS, Ahmed R. Models of immune memory. on the role of cross-reactive stimulation, competition, and homeostasis in maintaining immune memory. Proc Natl Acad Sci USA 1998;95:14926-14931.
42. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
43. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 1999;19:1-4-7.
44. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001;2:95-101.
45. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996;87:1037-1047.
46. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998;391:799-803.
47. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187:655-660.
48. Voigt I, Camacho SA, de Boer BA, Lipp M, Forster R, Berek C. CXCR5-deficient mice develop functional germinal centers in the splenic T cell zone. Eur J Immunol 2000;30:560-567.
49. Ansel KM, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000;406:309-314.
50. Hargreaves DC, et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001;194:45-56.
51. Wehrli N, et al. Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes. Eur J Immunol 2001;31:609-616.
52. Kaiser E, Forster R, Wolf I, Ebensperger C, Kuehl WM, Lipp M. The G protein-coupled receptor BLR1 is involved in murine B cell differentiation and is also expressed in neuronal tissues. Eur J Immunol 1993;23:2532-2539.
53. Forster R, Emrich T, Kremmer E, Lipp M. Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood 1994;84:830-840.
54. Roy MP, Kim CH, Butcher EC. Cytokine control of memory B cell homing machinery. J Immunol 2002;169:1676-1682.
55. Rollins BJ. Chemokines. Blood 1997;90:909-928.
56. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-1109.
57. D'Apuzzo M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 1997;27:1788-1793.
58. Imai K, et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol 1999;106:905-911.
59. Peled A, et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 1999;104:1199-1211.
60. + T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. J Exp Med 1998;187:1439-1449.
61. Kawabata K, et al. A cell-antonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci USA 1999;96:5663-5667.
62. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999;10:463-471.
63. Qin S, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;101:746-754.
64. Zlomik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127.
65. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
66. Bowman EP, et al. Developmental switches in chemokine response profiles during B cell differentiation and maturation. J Exp Med 2000;191:1303-1318.
67. Hauser AE, et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 2002;169:1277-1282.
68. Vincent T, Jourdan M, Sy MS, Klein B, Mechti N. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. J Biol Chem 2001;276:14728-14736.
69. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995;85:487-494.
70. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002;169:4213-4221.
71. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001;97:1817-1822.
72. Underhill GH, Minges Wols HA, Fornek JL, Witte PL, Kansas GS, Minges-Wols HA. IgG plasma cells display a unique spectrum of leukocyte adhesion and homing molecules. Blood 2002;99:2905-2912.
73. Qin D, et al. Fc gamma receptor IIB on follicular dendritic cells regulates the B cell recall response. J Immunol 2000;164:6268-6275.
74. Takahashi Y, Dutta PR, Cerasoli DM, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J Exp Med 1998;187:885-895.
75. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 1998;16:261-292.
76. Cassese G, et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001;31:2726-2732.
77. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
78. Difilippantonio MJ, et al. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med 2002;196:469-480.
79. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-932.
80. Bataille R, Haroussean JL. Multiple myeloma. N Engl J Med 1997;336:1657-1664.
81. Rettig MB, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997;276:1851-1854.
82. Gado K, Domjan G, Hegyesi H, Falus A. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell Biol Int 2000;24:195-209.
83. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med 2002;53:629-657.
84. Podczaski E, Cain J. Multiple myeloma. Clin Obstet Gynecol 2002;45:928-938.
85. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003;97:796-801.
86. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
87. Jego G, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999;94:701-712.
88. + subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 1999;105:131-140.
89. Arpin C, et al. The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene. Cmu-Cdelta switch, and lambda light chain expression. J Exp Med 1998;187: 1169-1178.
90. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Nad Acad Sci USA 1996;93:13931-13936.
91. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001;19:595-621.
92. + cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997;89:1824-1833.
93. + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995;85:436-447.
94. Bergsagel PL, Masellis Smith A, Belch AR, Pilarski LM. The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Curr Top Microbiol Immunol 1995;194:17-24.
95. + B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol 1999;106:545-552.
96. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. Br J Haematol 2002;116:429-435.
97. Fisher RC, Lovelock JD, Scott EW. A critical role for PU.1 in homing and long-term engraftment by hematopoietic stem cells in the bone marrow. Blood 1999;94:1283-1290.
98. Kim N, Martin TE, Simon MC, Storb U. The transcription factor Spi-B is not required for somatic hypermutation. Mol Immunol 2003;39:577-583.
99. Billadeau D, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996;88:289-296.
100. Fenton JA, Pratt G, Rawstron AC, Morgan GJ. Isotype class switching and the pathogenesis of multiple myeloma. Hematol Oncol 2002;20:75-85.
101. Pilarski LM, Masellis-Smith A, Szczepek A, Mant MJ, Belch AR. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk Lymphoma 1996;22:375-383.
102. Reiman T, et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001;98:2791-2799.
103. Taylor BJ, et al. Intraclonal homogeneity of clonotypic immunoglobuhn m and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone. Clin Cancer Res 2002;8:502-513.
104. Odendahl M, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-5979.
105. Putterman C, Deocharan B, Diamond B. Molecular analysis of the autoantibody response in peptide-induced autoimmunity. J Immunol 2000;164:2542-2549.
106. Jacobi AM, Hansen A, Burmester GR, Dorner T, Lipsky PE. Enhanced mutational activity and disturbed selection of mutations in V(H) gene rearrangements in a patient with systemic lupus erythematosus. Autoimmunity 2000;33:61-76.
107. Manheimer-Lory AJ, Zandman-Goddard G, Davidson A, Aranow C, Diamond B. Lupus-specific antibodies reveal an altered pattern of somatic mutation. J Clin Invest 1997;100:2538-2546.
108. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-766.
109. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-350.
110. Wakeland EK, Wandstrat AE, Liu K, Morel L. Genetic dissection of systemic lupus erythematosus. Curr Opin Immunol 1999;11:701-707.
111. Drake CG, Rozzo SJ, Vyse TJ, Palmer E, Kotzin BL. Genetic contributions to lupus-like disease in (NZB x NZW)F1 mice. Immunol Rev 1995;144:51-74.
112. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243-269.
113. Kono DH, Theofilopoulos AN. Genetics of systemic autoimmunity in mouse models of lupus. Int Rev Immunol 2000;19:367-387.
114. Mohan C. Murine lupus genetics: lessons learned. Curr Opin Rheumatol 2001;13:352-360.
115. Rudofsky UH, Evans BD, Balaban SL, Mottironi VD, Gabrielsen AE. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest 1993;68:419-426.
116. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994;1:219-229.
117. Morel L, Yu Y, Blenman KR, Caldwell RA, Wakeland EK. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm Genome 1996;7:335-339.
118. Morel L, et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci USA 2000;97:6670-6675.
119. Radic MZ, Mackle J, Erikson J, Mol C, Anderson WF, Weigert M. Residues that mediate DNA binding of autoimmune antibodies. J Immunol 1993;150:4966-4977.
120. Godessart N, Kunkel SL. Chemokines in autoimmune disease. Curr Opin Immunol 2001;13:670-675.
121. Russell PJ, Hicks JD, Burnet FM. Cyclophosphamide treatment of kidney disease in (NZB x NZW)F1 mice. Lancet 1966;1:1280-1284.
122. Russell PJ, Hicks JD. Cyclophosphamide treatment of renal disease in (NZB x NZW)F1 hybrid mice. Lancet 1968;1:440-441.
123. Boumpas DT, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-745.
124. Austin HA III, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619.